Castle Biosciences, Inc. (CSTL)
Castle Biosciences, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Friendswood, TX, US. The stock last traded at $32.44, up 0.63% on the session, giving a market capitalisation of $991.1M. On trailing twelve-month figures it carries a trailing P/E of -49.19, a net margin of -5.4%. Its beta of 0.97 implies it has historically moved less than the broad market.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Castle Biosciences, Inc. is most often compared with the following Healthcare names: